US-based checkout startup Bolt is raising $27 million in new funds to stabilize its operations. The company has seen its valuation drop from $11 billion to roughly $300 million. A new 'pay-to-play' structure will force existing investors to contribute more money or risk their shareholdings being significantly diluted.
Bolt, a US-based checkout processing startup, is attempting to secure a $27 million bridge financing round as it struggles to maintain its operations. The company, once a high-flying unicorn valued at $11 billion, is now facing a drastically reduced valuation of approximately $300 million. This move comes as founder Ryan Breslow, who returned as CEO, tries to navigate the firm toward profitability through a major shift in its business strategy.
This funding round is structured with a 'pay-to-play' provision. For investors, this term means that existing shareholders must choose to participate in this new funding round or face a reduction in their ownership stake. Essentially, those who do not contribute additional cash to the company may see the value of their existing shares diluted significantly. This structure is often used by companies in distress to ensure that current backers remain committed to the business during difficult times.
The firm has undergone massive changes to reduce its burn rate over the last few years. According to internal reports, the company’s headcount has been cut significantly, moving from roughly 900 employees in 2021 to about 60 today. The CEO has argued that the company is now leaner and using artificial intelligence to ship products faster, but the journey to sustainability has been difficult. The company has previously dealt with leadership changes and a stalled $450 million funding attempt, which faced challenges from investors.
It is important for Indian investors to distinguish this company from other entities using similar names. This Bolt is a private US-based fintech startup. It is not the same as the 'BSE Online Trading' (BOLT) system used on Indian stock exchanges, nor is it the publicly traded company Bolt Biotherapeutics (NASDAQ: BOLT) that operates in the healthcare sector. This news is specific to the private US checkout technology business.
Moving forward, the company is attempting to pivot toward a 'super app' model that aims to combine peer-to-peer payments, cryptocurrency, and credit features into its checkout software. The success of this pivot, along with the ability to secure this $27 million lifeline, will determine if the company can survive its current financial challenges. Investors following the global startup scene will be monitoring whether the firm can actually reach a sustainable profit level with its significantly smaller team and new business model.